Oct. 27 at 12:16 PM
$CRSP
From ntla board
$NTLA Intellia Therapeutics Says Its Temporarily Halting Patient Dosing, Screening For MAGNITUDE, MAGNITUDE-2 Phase 3 Clinical Studies Of Nex-z Patients With Transthyretin Amyloidosis With Cardiomyopathy
Intellia Therapeutics, Inc. (NTLA) , a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company has temporarily paused patient dosing and screening for its MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN), respectively.
This action follows a report on October 24, 2025 of Grade 4 liver transaminases and increased total bilirubin in a patient who was dosed with nex-z in the MAGNITUDE trial on September 30, 2025, meeting the trial's protocol-defined pausing criteria. The patient was hospitalized, is
